These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33747714)

  • 21. Selection Bias in Health Research: Quantifying, Eliminating, or Exacerbating Health Disparities?
    Rojas-Saunero LP; Glymour MM; Mayeda ER
    Curr Epidemiol Rep; 2024 Mar; 11(1):63-72. PubMed ID: 38912229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Semi-Parametric Estimation and Inference for the Mean Outcome of the Single Time-Point Intervention in a Causally Connected Population.
    Sofrygin O; van der Laan MJ
    J Causal Inference; 2017 Mar; 5(1):. PubMed ID: 29057197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dealing with time-dependent exposures and confounding when defining and estimating attributable fractions-Revisiting estimands and estimators.
    Steen J; Morzywołek P; Van Biesen W; Decruyenaere J; Vansteelandt S
    Stat Med; 2024 Feb; 43(5):912-934. PubMed ID: 38122818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Causal interpretation of the hazard ratio in randomized clinical trials.
    Fay MP; Li F
    Clin Trials; 2024 Apr; ():17407745241243308. PubMed ID: 38679930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
    Mitroiu M; Oude Rengerink K; Teerenstra S; Pétavy F; Roes KCB
    Trials; 2020 Jul; 21(1):671. PubMed ID: 32703247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Causal Inference for a Population of Causally Connected Units.
    van der Laan MJ
    J Causal Inference; 2014 Mar; 2(1):13-74. PubMed ID: 26180755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Causal inference using observational intensive care unit data: a scoping review and recommendations for future practice.
    Smit JM; Krijthe JH; Kant WMR; Labrecque JA; Komorowski M; Gommers DAMPJ; van Bommel J; Reinders MJT; van Genderen ME
    NPJ Digit Med; 2023 Nov; 6(1):221. PubMed ID: 38012221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulating and Answering High-Impact Causal Questions in Physiologic Childbirth Science: Concepts and Assumptions.
    Snowden JM; Tilden EL; Odden MC
    J Midwifery Womens Health; 2018 Nov; 63(6):721-730. PubMed ID: 29883521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimands-A Basic Element for Clinical Trials.
    Pohl M; Baumann L; Behnisch R; Kirchner M; Krisam J; Sander A
    Dtsch Arztebl Int; 2021 Dec; 118(51-52):883-888. PubMed ID: 34857075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considerations for master protocols using external controls.
    Chen J; Li XN; Lu CC; Yuan S; Yung G; Ye J; Tian H; Lin J
    J Biopharm Stat; 2024 Feb; ():1-23. PubMed ID: 38363805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence, per-protocol effects, and the estimands framework.
    Keene O
    Pharm Stat; 2023; 22(6):1141-1144. PubMed ID: 37477077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depicting deterministic variables within directed acyclic graphs (DAGs): An aid for identifying and interpreting causal effects involving derived variables and compositional data.
    Berrie L; Arnold KF; Tomova GD; Gilthorpe MS; Tennant PWG
    Am J Epidemiol; 2024 Jun; ():. PubMed ID: 38918044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.
    Casey M; Degtyarev E; Lechuga MJ; Aimone P; Ravaud A; Motzer RJ; Liu F; Stalbovskaya V; Tang R; Butler E; Sailer O; Halabi S; George D
    Pharm Stat; 2021 Mar; 20(2):324-334. PubMed ID: 33155417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond.
    Rufibach K
    Pharm Stat; 2019 Mar; 18(2):145-165. PubMed ID: 30478869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theory and performance of substitution models for estimating relative causal effects in nutritional epidemiology.
    Tomova GD; Gilthorpe MS; Tennant PW
    Am J Clin Nutr; 2022 Nov; 116(5):1379-1388. PubMed ID: 36223891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choosing estimands in clinical trials with missing data.
    Mallinckrodt C; Molenberghs G; Rathmann S
    Pharm Stat; 2017 Jan; 16(1):29-36. PubMed ID: 27492760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multistate models as a framework for estimand specification in clinical trials of complex processes.
    Bühler A; Cook RJ; Lawless JF
    Stat Med; 2023 Apr; 42(9):1368-1397. PubMed ID: 36721334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example.
    Aroda VR; Saugstrup T; Buse JB; Donsmark M; Zacho J; Davies MJ
    Diabetes Obes Metab; 2019 Oct; 21(10):2203-2210. PubMed ID: 31168921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimands in observational studies: Some considerations beyond ICH E9 (R1).
    Li H; Wang C; Chen WC; Lu N; Song C; Tiwari R; Xu Y; Yue LQ
    Pharm Stat; 2022 Sep; 21(5):835-844. PubMed ID: 35128808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Separable effects for adherence.
    Wanis KN; Stensrud MJ; Sarvet AL
    Am J Epidemiol; 2024 Aug; ():. PubMed ID: 39142687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.